Showing results (1491-1500 of 1,658) with videos related to

Sort By:
Pageof 166
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 18, 2010
Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasiaSachin Wani, Sharad C Mathur, Wouter L Curvers, et al.
AIDS (London, England)|December 22, 1999
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapyJ M Prins, S Jurriaans, R M van Praag, et al.
BMC Biotechnology|May 22, 2009
Peroxicretion: a novel secretion pathway in the eukaryotic cellCees M J Sagt, Peter J ten Haaft, Ingeborg M Minneboo, et al.
Open Heart|April 6, 2023
Ventricular function and biomarkers in relation to repair and pulmonary valve replacement for tetralogy of FallotJelle P G van der Ven, Marie Günthel, Eva van den Bosch, et al.
Medical Teacher|August 9, 2013
Online formative tests linked to microlectures improving academic achievementRianne A M Bouwmeester, Renske A M de Kleijn, Astrid W M Freriksen, et al.
Lung Cancer (Amsterdam, Netherlands)|August 29, 2020
Exploring imaging features of molecular subtypes of large cell neuroendocrine carcinoma (LCNEC)B C M Hermans, S Sanduleanu, J L Derks, et al.
Lancet (London, England)|July 8, 1998
Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigenF ter Borg, F J ten Kate, H T Cuypers, et al.
Blood|March 24, 2005
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabineRuben A Mesa, David Loegering, Heather L Powell, et al.
Journal of Clinical Immunology|June 14, 2001
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletionR M van Praag, J M Prins, M T Roos, et al.
Breast Cancer Research and Treatment|September 8, 2019
Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?T G Steenbruggen, N I Bouwer, C H Smorenburg, et al.
Pageof 166